undamentalytics Newsletter
Sign in

TG Therapeutics, Inc. income statement

In fiscal 2025, TG Therapeutics, Inc. reported revenue of $616m, up 87.3% on the year before, operating income of $123m (a 20.0% margin) and net income of $447m, or $2.77 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0000073234329616800
Cost of revenue—————101438101141
Gross profit—————63220291516659
Research and development691031591541662231257694160226
Selling, general and administrative———1510812895123154232296
General and administrative101615————————
Operating income−79−119−174−169−274−345−2182142123136
Interest expense—115661013242737
Income before tax−78−0−0−0−0−348−2241326107102
Income tax000000002−340−340
Net income−78−118−173−173−279−348−2241323447441
Diluted EPS−$1.60−$1.91−$2.30−$1.96−$2.42−$2.63−$1.65$0.09$0.15$2.77$2.77
Diluted shares (average)49m62m75m88m115m132m135m149m160m161m159m
EBITDA−79−119−174−169−273−344−2182142123136

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: TGTX vs TLXASND vs TGTXIONS vs TGTXRARE vs TGTX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from TG Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to TG Therapeutics, Inc.